NX-5948 vs Pirtobrutinib for Chronic Lymphocytic Leukemia
What You Need to Know Before You Apply
What is the purpose of this trial?
The study will evaluate the efficacy and safety of NX-5948 (bexobrutideg) versus pirtobrutinib in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who are relapsed or refractory to prior covalent Bruton tyrosine kinase inhibitor (cBTKi) treatment.
Who Is on the Research Team?
Study Director
Principal Investigator
Nurix Therapeutics, Inc.
Are You a Good Fit for This Trial?
This trial is for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose disease has come back or stopped responding after at least one previous treatment that included a specific type of drug called a covalent BTK inhibitor. Participants need to be in fair physical condition and have working organs.Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- NX-5948
- Pirtobrutinib
Trial Overview
The study compares two medicines, NX-5948 and pirtobrutinib, to see which works better and is safer for people with relapsed or refractory CLL/SLL. Patients are randomly assigned to receive either NX-5948 or pirtobrutinib.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Nurix Therapeutics, Inc.
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.